Computer-Aided Drug Design: An Overview.
暂无分享,去创建一个
[1] E. Poluzzi,et al. The hERG K+ channel: target and antitarget strategies in drug development. , 2008, Pharmacological research.
[2] Jeffrey J Sutherland,et al. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. , 2012, Journal of medicinal chemistry.
[3] Natalia Novac,et al. Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.
[4] Graeme Milligan,et al. High-Throughput Identification and Characterization of Novel, Species-selective GPR35 Agonists , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[5] Piero Procacci,et al. Reformulating the entropic contribution in molecular docking scoring functions , 2016, J. Comput. Chem..
[6] Nathan Brown,et al. Exploiting QSAR methods in lead optimization. , 2006, Current opinion in drug discovery & development.
[7] X. Barril,et al. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.
[8] Michael S Bodnarchuk,et al. Water, water, everywhere… It's time to stop and think. , 2016, Drug discovery today.
[9] Alan Talevi. Tailored Multi-Target Agents. Applications and Design Considerations. , 2016, Current pharmaceutical design.
[10] Markus Hartenfeller,et al. De novo drug design. , 2010, Methods in molecular biology.
[11] Antonio Lavecchia,et al. Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.
[12] M. Markowicz,et al. Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests , 2011, International journal of molecular sciences.
[13] M. Pangalos,et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.
[14] M. Gilson,et al. Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.
[15] Alan Talevi,et al. Combined Virtual Screening Strategies , 2009 .
[16] Dennis M. Krüger,et al. Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.
[17] C. Harris,et al. The Design and Application of Target-Focused Compound Libraries , 2011, Combinatorial chemistry & high throughput screening.
[18] Matthew E Welsch,et al. Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.
[19] J. Correa-Basurto,et al. Automated docking for novel drug discovery , 2013, Expert opinion on drug discovery.
[20] Jonathan Knowles,et al. A guide to drug discovery: Target selection in drug discovery , 2003, Nature Reviews Drug Discovery.
[21] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[22] Richard B. Smith,et al. Repositioned drugs: integrating intellectual property and regulatory strategies , 2011 .
[23] Ruibo Wu,et al. Molecular Dynamics-Based Virtual Screening: Accelerating the Drug Discovery Process by High-Performance Computing , 2013, J. Chem. Inf. Model..
[24] C. Laggner,et al. Why drugs fail--a study on side effects in new chemical entities. , 2005 .
[25] Jahan B Ghasemi,et al. Methods and applications of structure based pharmacophores in drug discovery. , 2013, Current topics in medicinal chemistry.
[26] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[27] Jianfeng Pei,et al. Binding site detection and druggability prediction of protein targets for structure-based drug design. , 2013, Current pharmaceutical design.
[28] Nathan Brown,et al. Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.
[29] Alan Talevi,et al. Antiepileptic Drug Discovery , 2016, Methods in Pharmacology and Toxicology.
[30] Bradley C Doak,et al. How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. , 2016, Journal of medicinal chemistry.
[31] Forbes J. Burkowski,et al. A constructive approach for discovering new drug leads: Using a kernel methodology for the inverse-QSAR problem , 2009, J. Cheminformatics.
[32] Shweta Gupta,et al. Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems , 2013, ISRN pharmaceutics.
[33] Ruth Nussinov,et al. Deterministic Pharmacophore Detection Via Multiple Flexible Alignment of Drug-Like Molecules , 2007, RECOMB.
[34] Christopher J. H. Porter,et al. Computational prediction of formulation strategies for beyond-rule-of-5 compounds. , 2016, Advanced drug delivery reviews.
[35] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[36] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[37] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[38] A. Brown,et al. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. , 2009, Bioorganic & medicinal chemistry letters.
[39] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[40] Sally Robinson,et al. Reducing attrition in drug development: smart loading preclinical safety assessment. , 2014, Drug discovery today.
[41] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS Chemical Neuroscience.
[42] Christian N. S. Pedersen,et al. Methods for Similarity-based Virtual Screening , 2013, Computational and structural biotechnology journal.
[43] Valerie J. Gillet,et al. Generation of multiple pharmacophore hypotheses using multiobjective optimisation techniques , 2004, J. Comput. Aided Mol. Des..
[44] Martin Pouliot,et al. Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research. , 2016, Journal of medicinal chemistry.
[45] Fabrizio Giordanetto,et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. , 2014, Chemistry & biology.
[46] Alan Talevi,et al. Computational approaches for innovative antiepileptic drug discovery , 2016, Expert opinion on drug discovery.
[47] Hiromasa Kaneko,et al. Inverse QSPR/QSAR Analysis for Chemical Structure Generation (from y to x) , 2016, J. Chem. Inf. Model..
[48] Brian K. Shoichet,et al. Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..
[49] Khusru Asadullah,et al. What makes a good drug target? , 2011, Drug discovery today.
[50] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[51] Jennifer L. Knight,et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.
[52] Tian Zhu,et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.
[53] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[54] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[55] X. Barril. Druggability predictions: methods, limitations, and applications , 2013 .
[56] Christopher A Lipinski,et al. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. , 2016, Advanced drug delivery reviews.
[57] Qiang Zhang,et al. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.